Podcasts about Chemotherapy

A new review paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.” Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells. In his latest review, Mikhail V. Blagosklonny, M.D., Ph.D., from Roswell Park Comprehensive Cancer Center discusses the theory that cancer resistance to certain therapies can be exploited for protection of normal cells—simultaneously enabling the selective killing of resistant cancer cells by using antagonistic drug combinations, which include cytotoxic and protective drugs. “No cancer cell, no matter how resistant it is, can survive chemotherapy in a cell culture. In the organism, however, therapy of cancer is limited by killing or damaging normal cells. Selective protection of normal cells from chemotherapy would increase the therapeutic window, improving the therapeutic outcome. Needless to say, reduction of side effects and better quality of life are very important for a cancer patient.” Depending on the mechanisms of drug-resistance in cancer cells, the protection of normal cells can be achieved with inhibitors of CDK4/6, caspases, Mdm2, mTOR, and mitogenic kinases. When normal cells are protected, the selectivity and potency of multi-drug combinations can be further enhanced by adding synergistic drugs, in theory, eliminating the deadliest cancer clones with minimal side effects. “I also discuss how the recent success of Trilaciclib may foster similar approaches into clinical practice, how to mitigate systemic side effects of chemotherapy in patients with brain tumors and how to ensure that protective drugs would only protect normal cells (not cancer cells) in a particular patient.” Read the full review: DOI: https://doi.org/10.18632/oncotarget.28382 Correspondence to: Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com Keywords: oncology, resistance, cyclotherapy, trilaciclib, rapamycin About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Happy International Women's Day! If you're looking to learn about a rockstar woman scientist, check out Episode 40 - The Mirror Image Disaster. In it, we talk about Dr. Frances Oldhem Kelsey, the FDA scientist who single-handedly fought to keep Thalidomide off the market and out of our medicine cabinets. In today's episode, Harini teaches Megan about how one of the biggest Allied cover-ups in WWII history led to the discovery and development of chemotherapy. During WWII, German bombers devastated the port of Bari, Italy where Allied personnel were stationed. Soldiers who were launched into the harbor, but survived the bombing, began to experience severe blistering and heightened internal temperatures. American doctor and chemical warfare expert, Stewart Francis Alexander, believed that all symptoms pointed to mustard gas. But when his report to Allied leaders was met with indifference and exasperation, he knew he had stumbled upon a possible conspiracy. Why were they denying the presence of mustard gas in the bay? Why was this form of gas causing these specific symptoms? Tune in to find out.See omnystudio.com/listener for privacy information.

Enzyme Therapy and Cancer - Getting To The Root Cause of Cancer - Dr. Linda Isaacs | Podcast #383 Dr. Linda's website: https://www.drlindai.com/ Schedule a FREE Consult: http://www.justinhealth.com/free-consultation Coffee Enemas: A Narrative Review: https://drive.google.com/file/d/1bY6AvGT4cNVvBx1CypSee-PD4m9Jo462/view?usp=sharing 04:08 - Views on Carbs and Fats Leading to Cancer 08:32 - Type of Enzymes for Cancer Treatment 14:02 - Potential Root Causes for Cancer 19:51 - When to check if it is a Gut Problem 22:52 - Preventing the Side Effects of Chemotherapy 33:11 - Chemotherapy Standard Care and Managing Side Effects 39:15 - Antioxidants Support   Podcast transcription: https://justinhealth.com/enzyme-therapy-and-cancer-getting-to-the-root-cause-of-cancer-dr-linda-isaacs-podcast-384/ Review us at: http://www.beyondwellnessradio.com/itunes   In this video, Dr. Justin and Dr. Linda discuss an educational and informative discussion about enzyme therapy and its relationship to cancer. In addition, she highlights her close connection to the late Dr. Nicholas Gonzalez, a former doctor in New York City and a follower of Dr. William Donald Kelly's work. The podcast covers various essential topics related to cancer and alternative therapies. Dr. Isaacs delves into metabolic types and how different individuals may require other treatment approaches. She also touches upon the impact of processed sugar, processed foods, pesticides, and xenoestrogens on cancer growth. Dr. Isaacs emphasizes the need to treat cancer holistically and believes that these environmental elements might substantially impact the development of cancer. ===================================== Gluten Video Series: http://www.justinhealth.com/gluten-video-series Thyroid Hormone Balance Video Series: http://www.justinhealth.com/thyroid-hormone-balance Female Hormone Balance Video Series: http://www.justinhealth.com/female-hormone-balance ===================================== ***Click below to SUBSCRIBE for more Videos http://www.youtube.com/subscription_center?add_user=justinhealth ===================================== Dr. Justin Marchegiani Email: office@justinhealth.com Newsletter: http://www.justinhealth.com/newsletter Google +: https://plus.google.com/u/0/b/115880353981241082117/115880353981241082117/ Visit us at: http://www.JustInHealth.com Facebook: http://www.facebook.com/justinhealthwellnessclinic Twitter: http://www.twitter.com/just_in_health Linked In: http://www.linkedin.com/pub/dr-justin-marchegiani/56/804/50a/

After being diagnosed with breast cancer at 30 and going through 8 rounds of chemotherapy, Alina Mehrle was left with dehydrated and fragile skin. The challenges with restoring her youthful and healthy skin inspired her to launch her own skincare brand, AMEŌN, which balances nature and the achievements of modern science. Founder story: from architecture to beauty, her courageous and inspiring story to building a brand. AMEŌN skincare: She spent 2 years developing products that nourish the skin and tap into healing mineral energy, micronutrients, and biotech.Chemotherapy's effects on the skin and her recommendations for skin and beautyCryotherapy: the benefits of skin icing and how to use the Frozen Essence at-homeEthics of using “natural ingredients” and why her scientists stand behind “naturally derived.”

Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses the most important lymphoma studies presented at the 2022 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/Lymphoma).

In today's interview, Jan sits down with Dom Dundee, one of the original members of the JJD Thoughts blog. For those of you that are unaware of Apex Communications Network's history, the JJD Thoughts Blog was a blog dedicated to mental, physical, and spiritual health written by Jan Almasy, Dom Dundee, and Jacob Sowers.Although the original blog crew broke up, all members have stayed close friends over the years, and have consistently provided inspiration to Jan as he built Apex. In this episode, Jan and Dom get the chance to catch up on life over the past three years.From reminiscing on powerlifting together in college to Dom's cancer journey and Jan's trip to Uganda - this is an emotional and wisdom-packed episode you won't want to miss.A huge thank you to Dom for being willing to share his journey with us. If you'd like to support Dom on his journey to raising funds for Cancer Research by competing in Spartan Races, click here.Message from Dom:I'd be remissed if I didn't name some specific people who really helped me in this journey. With this being first time I went real public with my full journey, I'd like to publically thank those people. My parents: moved into my 2 bedroom apartment for a year and half to help with my treatment. My dad was with me through every single chemo treatment and was my rock on the hardest days. My mom was the example being a cancer survivor and also gave me a shoulder to cry on.  Nothing I say will ever put into words how blessed I am for them. Katie Gilinsky, Alex Gilinsky, Jane Zentko, Janet Liffko McLeod, Diane Pavlic Zentko, and rest of my Florida family: the care packages, prayers, and texts were constant. I can't see you all in few months and celebrate. Rose Tupta and Laura Dwyer : my nurses and two of my closest friends. They talked me off more ledges than I can even count. Sam Heredos, Abbi Heredos, John Horvath Jr., Sean Sekola, Sarella Sekola , Chad Nasci: Some of my longest time friends who didn't flinch a second in their support for me. Elaina Tatro, Kyle Barkhurst, Charity 6 Foundation : gifted me signed Browns jerseys for my birthday that brought a smile to my face when smiles were hard to come by. Nicky Kozenko Vojtush, Ryan Peter Vojtush, Erica Jean : thank you for supporting from a work stand point and never flinching in support as friends. If you're listening, and someone with an amazing story comes to mind, we'd love an introduction! Even if the person has never been on a podcast before, we would be honored to be their first interview. Please submit a “Guest Referral” form hereFollow Us on Social: Jan Almasy: https://www.linkedin.com/in/jan-almasy-57063b34RJ Holliday: https://www.linkedin.com/in/robert-j-holliday-jr-b470a6204/ James Warnken: https://www.linkedin.com/in/jameswarnken --LinkedIn: https://www.linkedin.com/company/51645349/Facebook: https://www.facebook.com/ApexCommunicationsNetworkWebsite: https://www.apexcommunicationsnetwork.com

Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York City discusses the management of desmoid tumors. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayDesmoidTumors22).

How can we find emotional healing through creativity and art? This week's amazing guest offers his insights from his personal healing journey during the process of publishing a powerful and inspiring children's book he co-authored with his late wife. Matthew Ronan likes telling good stories, helping others tell good stories, and most of all wants his life to be a good story. He is an artist, writer, and content producer who's worked in film, television, and radio. His credits include projects for Disney/Lucasfilm, Warner Bros., 20th Century Fox, and the Michael Jackson estate. He lives in San Francisco with his daughter Catica. Chastidy Ronan was an executive director of a family support center, a teacher, a missionary, and a nanny, but the brightest part of her life was being a mom. She taught elementary through college in Ohio, Haiti, China, and San Francisco. She knew 5 languages and always got the most blue ribbons in Toastmasters. She died in 2019 from colon cancer and is survived by her daughter Catica and her husband Matthew. Matthew shares his heart-gripping story of multiple miscarriages, his wife's diagnosis of stage four cancer when their daughter was five months old, and the simultaneous dissolution of the company he had founded during Chastidy's illness. Ronan relates the original dream he shared with his wife about writing children's books. He notes how life became too busy to follow this dream until they resurrected the idea during Chastidy's battle with cancer. Chemotherapy regimens and caring for their young daughter made writing difficult, so Ronan had to finish the book after his wife passed away. Matthew recounts the challenges of navigating life as a creative professional. He notes the fears that seized him as he worked on the book, especially after facing multiple traumatic losses with regard to his family, previous creative projects, and the dissolution of his company. Ronan details how God worked on his heart as he worked through the chapters of the book. The Lord shifted his perspective from worldly success standards toward inspiring others. The mindset change freed Matthew from worry and anxiety. We address the irony of how those who serve in the healing media of art suffer great attacks on their emotional wellbeing, identity, and discouragement. Matthew discusses the sensitivity of creatives as part of their power to offer emotionally transformative work. The emotional nature of an artist also renders them vulnerable to pain. Ronan highlights the cultural pressures and intense competition of the artistic industries. We discuss the issues of comparison and spiritual warfare faced by creatives. Matthew shares his recent encounter with a man armed with a knife who charged at Ronan and his six year-old daughter. He pointed out the incident occurred right before he was scheduled to share his testimony at an event. We also emphasize how those who do not work in creative arts industries can enjoy healing and connection with God through art. Matthew defines art as valuable to all people because it is the language of the heart. Ronan states that art is a tool that God uses for discipleship. He urges us to resist the temptation to ascribe value to our creative projects by comparing them to what others have produced. We differentiate between therapeutic art, healing art, art as worship and the art crafted as work. Matthew and Chastidy Ronan's book, The Girl With 5 Hearts, is about a girl who gives her hearts to the things that she loves, only to have them rejected and broken. It is a painfully honest, yet hopeful story about giving your heart back to the One who made it, because many things in life can break it. No stranger to heartbreak and loss Chastidy's inspiration for The Girl With 5 Hearts was autobiographic, at the same time universal. This story will inspire both young and old, and point towards healing even the deepest of wounds. Learn more and get your copy at the girlwithfivehearts.com Get your copy of a book to help you connect with the Lord's renewal through insightful study chapters, creative illustrations, and easy craft projects. Discover restoration through Upcycled: Crafted for a Purpose by Tina Yeager on Amazon, through Bold Vision Books, or wherever books are sold. https://www.amazon.com/Upcycled-Craft...

Chemotherapy, radiation, and surgery are the approved methods doctors use to conventionally treat cancer. These methods are tough on the body and they only treat the symptoms. What if there was another way? Dr. Leigh Erin Connealy is the author of “The Cancer Revolution,” and the medical director of the Center for New Medicine and the Center for Healing in California. She […] The post Leigh Erin Connealy, MD, A Mind, Body, Spirit, Approach to Cancer appeared first on LillianMcDermott.com.

Advanced practice providers (APPs) are a key component to effective team-based care, but what is it that our APP team-members can do in an oncology practice? Join the Co-hosts of the APP podcast series, Todd Pickard (MD Anderson Cancer Center) and Stephanie Williams (Northwestern University Feinberg School of Medicine), along with guests Wendy Vogel (BroadcastMed/APSHO)) and Tammy Triglianos (University of North Carolina Basnight Cancer Hospital), as they highlight the services and examples of what APPs in oncology can do, their role as an APP in team-based care, if and how they bill for their services, and how they are reimbursed.  Speaker Disclosures: Stephanie Williams: Consultant or Advisory Role – CVS Caremark Tammy Triglianos: Consulting or Advisory Role – Pfizer Todd Pickard: No relationships to disclose Wendy Vogel: No relationships to disclose  Resources: Podcast: Advanced Practice Providers - APPs 101: What and Who Are Advanced Practice Providers (APPs)? Podcast: Advanced Practice Providers – An APP's Scope of Practice Advanced Practice Providers - APPs 101: Physicians Assistants (PAs) and Advanced Practice Registered Nurses (APRNS) in Oncology If you liked this episode, please follow the show. To explore other educational content, including courses, visit education.asco.org. Contact us at education@asco.org. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Stephanie Williams: Hello, everyone, and welcome back to the ASCO Education podcast, and our fourth episode of the Advanced Practice Providers series. I'm Dr. Stephanie Williams, a medical oncologist, and your co-host for the series, along with physician assistant Todd Pickard. We'd also like to introduce you to our guest panelists today. Returning guest, Wendy Vogel, along with Tammy Triglianos. We'll take a moment to let them introduce themselves, starting with Wendy. Wendy Vogel: Hi. Thanks so much for having me today. I'm Wendy Vogel. I'm an oncology nurse practitioner by trade, and I am the Executive Director of APSHO, the Advanced Practitioner Society for Hematology and Oncology. And thanks for having me here today. I'm really excited to be here.  Dr. Stephanie Williams: Tammy.  Tammy Triglianos: Hi, everyone. Thank you for having me. And I'm excited to join this group for our conversation today. I'm Tammy Triglianos. I am a certified oncology nurse practitioner practicing in North Carolina. My career has been dedicated to caring for oncology patients, even starting out as a nursing assistant and then as a registered nurse practicing in a variety of settings. I've been a nurse practitioner for almost 20 years now, with the past 15 specializing in GI medical oncology.  Dr. Stephanie Williams: Thank you.  Todd Pickard: Thanks, everybody, for being here today.  Dr. Stephanie Williams: In today's episode, we will be highlighting the services and examples of what advanced practice providers in oncology can do and describing if and how they bill for their services and how they are reimbursed.  So let's get started. Wendy and Tammy, I'm starting in my clinic, 8:30 in the morning. We have a full panel of patients, patients who just need reassessment, chemotherapy prescribed, reevaluation, bone marrow biopsies, test results. How do we work together to see, as a team, these particular patients, or in other words, what can you do to help me through my days as an oncology practitioner?  Wendy Vogel: Wow, that's a great question to just jump right in and start with. I'm excited to talk about that. Well, I think that, you know, as we always are talking about our team approach, we would look at that schedule. And hopefully, the AP and you have their own schedule so that we're able to divide and conquer and be able to accomplish that schedule, see all the patients in the most efficient manner possible. Hopefully, I've looked at all my patients beforehand and see if there's anything that I need to collaborate with you on. Looking at our labs, you know, maybe scans, talking about any changes in plans that we might anticipate together, and so on.   Tammy, would you do the same?  Tammy Triglianos: Yeah, I'd like to echo your point, Wendy. Having independent schedules, I think, makes for a more efficient workflow in the clinic. And in my practice we have a team meeting with our clinical pharmacist, physician, myself, and our nurse navigator, and review last week's and even prep for the upcoming week, trying to anticipate and make sure people are set up and orders are in, and we're prepared for the week to come. Day of, as you know, can get pretty hectic. But since we've done a lot of that prep work, I think it makes for the unknowns that pop up in clinic easier to connect with each other, with my physician and other team members.  Todd Pickard: I agree. I think the great thing about how physicians and APPs work in teams is that the team can decide what's best. I have done everything from having my own independent template so that I have patients that I'm responsible for to a general template where the physician and I just divide and conquer at the beginning of clinic, and we say, “Okay, you see these patients, I'll see these patients, and we'll back each other up if we need to.” All the way to seeing every single patient along with the physician when we are seeing a lot of news and consults, very complex, very acutely ill patients. And we basically just work as a team the entire day on everything.  So it's really interesting about the conversation that I think we'll end up doing today is the “what” versus “how.” What APPs do is– really, honestly, APPs can do anything and everything unless a state scope of practice or an institution's policy specifically says they can't. That's the good news is that we pretty much can do everything but the “how,” that's a really interesting question because a lot of different things come into play. Position preferences, which could be influenced by their own personal experience or their own personal preferences of style versus, you know, having a misunderstanding of what APPs can and can't do. Then there's the institutional policies and the state scope of practices that come into play. So I think this where we'll end up spending some time today.  And, you know, Stephanie, maybe we could start the conversation with you a little bit around physician preferences and what your experience has been, and some of the things that you've noted around the physicians as part of this team.  Dr. Stephanie Williams: I've worked with APPs, both inpatient and outpatient, and I think it is very important to have that team-based approach. Patients really appreciate that, knowing that there is always a provider, someone there that they can turn to. And I think that's one of the great things about APPs is they always seem to be there for patients to turn to and for our nurses to turn to, to get help too. Both our clinic nurses, our infusion nurses, and our inpatient nurses really appreciate having that extra clinical provider available to them. I think as a physician, during my day, what I would like to see is us getting through our panels of patients, whether we're together, which is not as efficient as if we're independently seeing patients, but also help with things like procedures that need to be done on patients, phone calls at the end of the day, peer-to-peer reviews in order to get either medications or tests done for our particular patients. Filling out forms, no one likes doing that. No one likes filling out disability forms or other insurance forms, but those are all things that we all need help with in terms of doing. Ordering consults, seeing new patients together. I work in the transplant field, so they're complicated patients, so it actually is very helpful to have, to see a patient with your advanced practice provider so that you can come up with a treatment plan together that you know you can then follow throughout the course of hopefully that patient's treatment and recovery. Chemotherapy orders is another place that we need, that can be very valuable, whether it's the initial chemotherapy order, which were usually the physician or pharmacist initiated, but those follow-up chemotherapy appointments or problems in the infusion clinic are also helpful areas.  There are some physicians, though, who want to have an APP simply as their scribe, to follow them around in clinic and to then begin whatever orders they feel is appropriate for that particular patient. That is not the most efficient way to see patients, particularly when you have a large panel of patients that you have to see.  Wendy Vogel: Exactly. It really isn't. I will just tag off something you said about the AP being the scribe. That's probably one of the most expensive scribes that a physician could employ, and what a better use of our time is to not be a scribe. You know, there are other people who could really efficiently be a scribe better than the AP, and the AP could actually be seeing patients and gaining reimbursement for the practice.  Tammy Triglianos: An additional comment on team-based care. I work with a physician where we alternate visits, and I think that has really worked well in establishing a relationship with patients. We both have very high touch points with the patients, very involved, and patients feel like there's that team that's always available because always one of us is usually available. Dr. Stephanie Williams: How long did it take you all, all three of you, to develop that relationship with your physician colleagues to work tightly in a team? Todd Pickard: That's really a great question, Stephanie, because I think one of the strengths of the relationship is that level of trust and comfort and not really to view it as a hierarchical relationship, but really a team. We're there for each other. And you know, that depends, you know, there's personalities involved, people's previous experience, you know. If you've only had great experiences with APPs, probably trust them right away. If you've had difficult relationships with APPs or teams that didn't work well, it may take longer. I'd say the best approach is for both the APP and the physician to really look at this as, “How can we accomplish our work together that provides the best quality and the highest level of safety for our patients?” And really just set the expectations of ‘this is a trusting relationship where we work together, we support each other, and we're willing to talk about where the limits of our knowledge are. And for both of us, that's when we get consultations with other folks, and so we just approach it from this perspective.' And of course, you know,over time, that just strengthens and grows. And when you have a really good, strong, trusting relationship, that's where the real power of the team comes into play. Wendy Vogel: I like what you said about trusting. You know, the AP has to trust in the physician to be able to go and ask questions and to be mentored, and vice versa, too. I think we play to each other's strengths. If my strength is talking about hospice to a patient that needs to change trajectory of course, then maybe that's what I do better. And there are other things that another team member would do better, but feeling comfortable and saying, “You know, this is what I do good,” or, “Hey, I need help with this. I don't do this as well as I would like to.” Dr. Stephanie Williams: Tammy, anything? You said you work with one physician. How did that develop?  Tammy Triglianos: Right now, that's my current setup because of volumes, but I have worked with a team of physicians as well, which, when you're an APP working with a team of three, four plus physicians, that can kind of get a little bit tricky, people fighting for your time. I think being in parallel clinics has helped establish our trusting relationship because all day long, you're with that person navigating care together. We've been together probably 14 years, so that's really dipping back into my memory bank of the beginning of our time together. But I think it's what Wendy was talking about is just approaching each other with questions or, “Hey, why did you do that?” Or “Help me understand this.” And I think our approach to each other wasn't, “Why did you do that?” But, “Help me understand your thoughts on this.” Or “Can I talk through this with you to make sure I'm on the right page.” And how that response came back, then I think that has helped develop a trusting relationship.  Dr. Stephanie Williams: You both bring up excellent points because there still exists that power gradient between the physician, the advanced practice provider, and a staff nurse or an infusion nurse. And it's really important to overcome that so that people are comfortable in terms of taking care of the patient, to give the patient the best possible care that there is. Todd Pickard: Yeah, I mean, I think this is a great time to really just highlight the fact that there's a lot of misinformation and misunderstanding out there around APPs, what they can, what they can't do, what they will, what they won't do. In some corners, there's this fear that APPs will go rogue, and that will harm patients. And really, that is an irrational fear because when we are trained, we are trained very clearly about when you reach your own limits, that you are required and obligated as part of your professional practice to find that support, find those resources, get consultations, work with your team to understand so that you serve the patient. And I think it's really important that folks remember that with this respect and trust and accountability, because asking for help is not a failure. Asking for help shows a successful dynamic within a team so that the entirety of the team brings to bear their expertise, their knowledge, their skills, and their judgment. And when the team doesn't know what to do, that's when you've got to reach out to your consults and your other resources. So I think that's an important thing to remind everybody is that we're all here trying to do the same work, and it doesn't do any good if you spend a lot of time wondering, “What's Todd up to today?” So I think it's important to realize and for us to kind of dispel those kinds of myths. Wendy Vogel: I think, despite a social media post by one of our well-known medical associations that will remain unnamed, we don't think that healthcare is a game. We are absolutely serious about this, and we love taking care of our oncology patients. This is something that we're trained to do and that we want to work together as a team. Great thoughts, Todd. Dr. Stephanie Williams: In terms of actual practice in the states that you're at, are there any restrictions, either statewide, institution-wise, on what you can and can't do? Tammy Triglianos: I think a big topic that comes up a lot is signing treatment plans or antineoplastic treatment plans. And I don't know across the states, but in my state, that is not a state restriction. But not allowing APPs to sign antineoplastic treatment plans is more of an institutional restriction, and that varies. Recently, I was able to work with a team of people to update our policy to allow APPs to sign antineoplastic treatment plans and how it works at my institution, they go through a privileging process, so essentially it's an opt-in privilege. So, APPs can obtain approval to sign treatment plans, and it is restricted to cycle two and after. So the treatment plan initiation and signing the first cycle is done by the physician, and APP can place the treatment plan and get it teed up. But it actually is signed by a physician for cycle one, and then an APP is now allowed to sign beyond cycle one. We have a few guidelines like they have to be in their subspecialty practice and be manipulating treatment plans that are cosigned by the physician initially and have certain subspecialty training. So, yeah, I'm excited about this update to allow APPs to practice to the top of their license.  Todd Pickard: Stephanie, this is such an important concept and one that we have hit upon in all of our podcasts. And really, the limits of APPs outside of physician preferences are really state laws and institutional policies. And so, the answer to your question is ‘yes, and it depends on where you are'. So, for example– Tammy gave an example of what's going on in her institution. In my institution, all chemotherapy plans must have a double signature, whether it's initiated by a physician or a pharmacist, or an APP, and that's a safety and quality check. And so everybody just needs to understand, again, limits generally are only in state laws and institutional policies rather than what APPs are trained to do or what folks will reimburse for. And so, really, that's where you have to do the most detailed examination is: what state are you in and what does your institution or your practice say? Generally speaking, most states allow teams at the local level to kind of figure out what they want to do. Sometimes they'll limit a certain medication, like a schedule II drug or a certain other medication. Institutions sometimes do the same thing. But the good news is, if it's not explicit in state law, you can change institutional policy and physician preference all day long.  Wendy, what's your experience been?  Wendy Vogel: Oh, I totally agree. I think it's important for APs to know who's setting the institutional policies and for physicians to know this as well because it may be someone who is not familiar with what the AP role could really be. What do they know about the advanced practitioner? We mentioned that earlier. But I think it also brings up a very important gap that we've seen in oncology, is what's the training of the AP to be able to write anti-cancer therapy orders, and it's a wide variety. There are very few, for instance, nurse practitioner oncology certification or graduate programs. Most of us are trained in a generalist level as a family nurse practitioner. PAs, as you said before on this podcast, you are trained at a generalist level, and we get a lot of our specialty education on the job or through other advanced education. So we're coming into this at all different levels: brand new APs, brand new to oncology APs, and we've seen a gap at the educational level across the US is not the same.  One of the things that APSHO has done to relieve this, and I'm so excited to be able to share with you guys, is we've just recently launched the APSHO Cancer Therapy Prescribing Course. This, I think, will set the benchmark that we've just talked about and bridge this gap, and allow APs to really practice to the top of their licensure, as Tammy mentioned earlier. It's a very comprehensive online, self-paced course providing that advanced education to prescribe cancer therapies and to manage that hem/onc patient throughout the treatment trajectory. It does not just include the cancer therapies but other things we need to know as APs, like: what kind of drugs do we give with the cancer therapies, what are the standards of care, what do we do in clinical trials? And so just all this that we need to know, and I hope this will bridge that gap, if you will, for this education.  Dr. Stephanie Williams: Excellent points. I think it also requires physician education to know and understand what advanced practice providers can do. And I think an advantage to our younger generation physicians is that they are now growing up in institutions where APPs are normal, as opposed to older physicians like myself, where we really do have to learn what can be done and what can't be done so that we can trust what everyone is doing there. Todd Pickard: Are we normal? Yes. But what you really mean is that we're present. It's really about interprofessional education, and I think there's a lot of importance of that concept. If we're going to be delivering care in teams, we should be trained in teams so that you grow up side by side and so that way it does seem normal. I'm working in a team; where's the social worker? Where's the APP? You know, where's the pharmacist? Because that's how you trained, and that's how we really deliver care. That's the honest truth. No man or no woman is an island in medicine. We all work in teams, whether we recognize that or not. And so I think it's great when you hear about folks that are actually training side by side because it just dispels some of this anxiety, some of these misconceptions, and you're just used to the team being around, and it's like, “Okay, where's my team?” And then it doesn't become unusual. It's just normal. Wendy Vogel: Yeah, we're all sitting here nodding our heads together. You all can't see us, but we're all nodding. So, Stephanie, I really want to know, how do you educate your colleagues who might not be as receptive to the idea of an advanced practitioner writing cancer therapy orders? Dr. Stephanie Williams: I have to tell you, it's difficult sometimes, Wendy, or it has been difficult in the past. The problem becomes not so much a “do you know what you're doing,” problem is how does the reimbursement - I hate to say this – how does reimbursement figure into all this? If I let an APP see half of my patients, who gets that money? And then the other thing is just how do I efficiently use an APP? And we are trying, and  ASCO through the Clinical Practice Committee, to try to get out there and reach out to practices, particularly rural practices, to help them understand the role and the value of advanced practice providers. And I think it's going to be a reach-out effort, leading by example, showing people that this is the way we can do it and we have to do it this way because we need practitioners out there to take care of patients. Todd Pickard: I want us to all pause here because what you just talked about is critically important. And we all know this is part of medicine, whether we like it or not. But reimbursement, how we get paid, and productivity, how we are recognized for what we do, are concepts that sometimes get mixed up. So when you're talking about reimbursement, APPs are reimbursed just like physicians for everything that we do. Depending on who's paying the bill, they may reduce that reimbursement. So CMS reduces generally to 85% of the physician fees. Medicaid is all over the place, depending on your state and the third-party payers, like the commercial insurance, that's based on whatever you've negotiated in your contract. Sometimes it's a little, and sometimes it's the same. So APPs get reimbursed, period. What level they get reimbursed compared to the physician's reimbursement is really up to a lot of different factors.  But productivity, I think that's the thing that we really get hung up on is, well,who's going to get credit for this work? And guess what? The beauty of that is you get to decide. Every practice, every institution makes up those rules. And so, you know, the take-home message here is, don't confuse reimbursement with productivity. Reimbursement is a lot of external factors that are either statutory, or they're contractually negotiated. But productivity is an internal accounting, and you can use team-based metrics. Who's to stop you from saying ‘we reward and recognize both the physician and the APP in these teams.' They both get credit, and they both get productivity measurements and recognition. And so I think that's where we really need to drive home the message is it's not about setting each other up as competitors. It's redesigning our internal productivity measures so that it's collaborative and that all the work that's being done by the entire team is being recognized and rewarded. Wendy Vogel: A lot of what we do, as Stephanie referred to earlier, is not reimbursable. All those peer-to-peer reviews, we don't get paid for that. None of us do. Calling patients back, liaisoning with the nursing staff, and answering their questions through the triage line, so much of that is vital to supporting a practice, and you can't do it without all that, but it doesn't appear on the bean counter's metric sheet. So how do we do that? I don't have the answer to that. Tammy Triglianos: Yeah, and I think in oncology/hematology, there's a lot of frequent touch points in between provider visits, and that doesn't equate to money, but equates to high-quality care, to have access to skilled providers to help manage all the complications, and, you know,in between stuff that happens between provider visits. Dr. Stephanie Williams: Wendy, there have been changes now in terms of who can enroll and write treatment orders for patients on cancer clinical trials. Could you go over those changes with us and how APPs can now fully participate in this process? Wendy Vogel: So there were some recent changes to CTEP and then now allowing APs to sign clinical trial orders. This is huge because it really makes the process of getting patients their drugs in the infusion suite much quicker. We don't have to track down a physician to sign those clinical trial orders. The AP can do that. And so this process is made much smoother. I think we'll see a lot of other cooperative groups and institutions follow suit with this. And I think this was a real demonstration of the AP's quality of care and the safety of AP prescribing and being able to have this privilege. Todd Pickard: Well, this has been a fascinating conversation today, and I would like everybody to have a final say. What's your take-home message today about what APPs can and can't do. And Tammy, we'll start with you.  Tammy Triglianos: Thank you. This was a great conversation today. Happy to be a part of it. Know that APPs with supportive, appropriate training, and, you know, I just have to shout out to Wendy and APSHO for the chemo prescribing course. I think this is huge for bridging a gap. Lots of education programs don't have oncology subspecialty, and this is such a comprehensive course that bridges a gap that I think will be huge. And I hope every oncology cancer center adopts, incorporating this to elevate the education and offer some subspecialty education to our oncology APPs. Kudos for all the team-based care and physician and APP teams out there that are really working hard to care for our cancer patients. Todd Pickard: Wendy, what are some of your final thoughts? Wendy Vogel: I have to agree with Tammy. I'm really excited about the APSHO Cancer Therapy Prescribing Course. I think that we can, together as a team, really make a difference in cancer care, playing to each other's strengths, and I think that would be my takeaway is: how can we better play to each other's strengths? Todd Pickard: Stephanie, what about some of your final thoughts? Dr. Stephanie Williams: I think working with APPs is critical to the success of any medical practice and to any physician who takes care of patients. Todd Pickard: Well, I appreciate all the insights. And just as a reminder, APPs and physicians, generally speaking, can decide whatever they want that is best for the practice, best for their patients, and delivers high-quality and safe care. Just be aware of your state regulations and find those institutional policies that are holding you back. Good news on the institutional policies - you can change them just like you can change your productivity metrics and models. So the good word is APPs and physicians can work in amazing teams, and we have all the power at our disposal to do so.  Well, I want to thank you to my co-host, Dr. Williams, along with Wendy and Tammy, for joining our discussion today and sharing all of your experience and highlights into the services that APPs can deliver. It's clear that APPs and physicians working together in teams are vital to a strong and efficient delivery of our team-based care.  Well, until our next episode, thanks, everybody, and take care. Thank you for listening to the ASCO Education Podcast. To stay up to date with the latest episodes, please click subscribe. Let us know what you think by leaving a review. For more information, visit the Comprehensive Education Center at education.asco.org. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

An inspiring story of love, perseverance and the power of football - Bob Kessler is in awe of where his family was and where they are now. His son Tyler is a walking medical miracle. Tyler suffered from kidney failure when he was just four years old and received a transplant from his grandmother. But, in 2000 he was diagnosed with cancer and his body rejecting the kidney. Suffering from Post Transplant Lymphatic Disorder, he was the only child in the U.S who was undergoing chemo and dialysis at the same time.But Bob didn't want Tyler's childhood memories to only be hospitals and doctors. That's why he set a goal to visit every NFL stadium in the country. Starting the year Tyler was diagnosed, they traveled the country meeting player after player and coach after coach. Their story is not only a football fan's dream, but a lesson to us all to never let our struggle define our story.Additional Resources:Get Involved or Donate to the Make-A-Wish foundation to help change kids' lives: https://wish.org/Read about Tyler's story in Sports Illustrated: https://vault.si.com/vault/2005/01/31/the-best-medicineSupport the National Kidney Foundation: https://www.kidney.org/donationListen to More Revenue Builders: https://www.forcemanagement.com/revenue-builders-podcastHIGHLIGHTSIntroducing Bob KesslerTyler's background and storyStaying positive through the tough timesMaking tough decisions with your destination in mindVisiting stadiums with TylerThe value of being made to feel like you belongStories from inside the NFL locker rooms and busesFocusing on what you can do, not what you can'tAdvice for people facing challengesCommunity is more important than you realizeQUOTESBob - Remaining positive: “I will tell you, my wife and I, we agreed at a very early part of this journey that there's no complaining, there is no asking why? Because there's no answer there. All we know is what we can do.”Bob - Building community: “At first, you may be like, Hey, I don't need that. That's what we said, but give it a shot, and try to network and learn from others. You know, we learned a lot from families who have gone through, you know, you meet families in the hospital, who are going through similar challenges, some worse, and we've learned a lot by observing and talking to folks and sharing our story, and, what's the best way to work through all these challenges.”

Synopsis: Jack Bailey is the CEO of G1 Therapeutics, a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. Jack worked at Eli Lilly for 19 years followed by GSK for 12 years, and served on the company board at G1 Therapeutics before stepping into the role of CEO. Jack provides his perspective on the state of the industry and how the current macro environment is affecting financing, the supply chain, and attracting and retaining talent. He talks about his team's work at G1, the proactive approach they're taking to combat cancer, and the unique commercial aspect of the company. He also discusses the current legislative and regulatory environment, concerns he has, and opportunities for the future. Biography: As Chief Executive Officer, Jack Bailey leads G1 in its mission to fundamentally change the chemotherapy experience for patients with cancer. Mr. Bailey has over thirty years of commercial pharmaceutical experience and has an in-depth understanding of the healthcare marketplace. He has extensive experience in commercialization, health systems, health policy, and government affairs. Previously, Mr. Bailey led the GlaxoSmithKline pharmaceuticals and vaccines business as President of the U.S., with responsibility for commercialization efforts across the company—oncology, immunology/rare disease, respiratory, and vaccines portfolios. He also was a member of the company's Pharmaceutical Investment Board responsible for the clinical development investments by the company. Earlier in his career, he held various senior commercial leadership positions at Eli Lilly and Company, including Senior Vice President of the Account-Based Markets Division that included both the oncology and cardiovascular portfolios along with the managed markets groups. Mr. Bailey was appointed to the G1 Therapeutics Board of Directors in March 2020 and in September 2020, he was named CEO. He also serves on the board of the UNC Health System, Emergo Therapeutics, a privately-held biotechnology company, and is a past member of the board at Harvard T.H. Chan School of Public Health, the board of directors of PhRMA, the pharmaceutical industry trade association, and the North Carolina Biotechnology Center. He holds an MBA from the University of North Carolina and a B.S. in biology from Hobart College.

Kay has lived with various conditions since his teens. One of those is Ulcerative Colitis. He had been consistent going to the gym. Noticing the progress he had made. One day he noticed, he stopped. It had been a month, then 2. He was weak that he had to use crutches. Kay, went to the hospital. He had a 50% blood loss. He stayed in the hospital for 3 weeks. Slowly he gained his strength. He started to train while in the hospital. Sara's story starts around Christmas when she was diagnosed with Breast Cancer. Starting with Chemotherapy, they installed a port under her skin. This was the first operation she had since her fusion. Not having flash backs but remembering what it felt like to have surgery the emotions felt familiar. While this is going on, she was also getting certified in Steel mace flow. It took a while to get used to training with her mace while having the port under her skin. They share how the mace has helped with recovery. Sara shares the emotional space is huge. I'm the strongest I've ever been. The mace gives me a habit to move & think positively. Kay the mental as well physical were huge. Once I discovered the rotational line of movement, I discovered it heals entire body. His determination kept him motivated to revisit his training with the mace, no matter what the weight. When we have to take baby steps, it's an opportunity to self reflect. To hear more of their stories with Scoliosis, you can her Sara's here & Kay here. Where can you find Sara & Kay? Sara Instagram: Sarandipitous_life Kay Instagram: Kayola885 3 Free tips for back stretches created by Teresa for Scoliosis back pain. Grab your free tips here Do you follow Teresa on Instagram yet? Head over to T3Fitt on Instagram and follow her and her team for additional content. LEAVE A REVIEW: if you enjoy this episode, we'd to hear what was your take away. Be sure to do over to Apple Podcasts & leave a review. If you know someone who this can help please share. Take a screen shot & share it with us on instagram @T3fitt.

Dr Bob Li from Memorial Sloan Kettering Cancer Center in New York City discusses the current and future roles of targeted therapy for HER2-altered non-small cell lung cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2AlteredNSCLC22).

Alan interviews Leeanna Gantt. In 2018 Leanna Gantt endured a year of breast cancer therapy. Keeping track of all her medications was challenging - so she invented a better system: Tooktake. Today Tooktake sells in CVS and Walmart - helping people young and old to always be certain they took their medicine timely. Make sure to subscribe to the podcast at Apple Podcasts, or wherever you get your podcasts, so you won't miss a single episode. Website: www.Tooktake.com  

Dr Edward Garon from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, discusses the management of NSCLC in patients who do not have actionable activating mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCwithoutActionableMutation22).

Novel β-lactamase/β-lactamase inhibitors have become critical drugs to combat the most resistant Gram-negative infections. A series of new compounds with even more broad and potent activity are in the horizon to add to the therapeutic armamentarium. Today, we will discuss these drugs with experts in the field. Topics discussed: BL/BLI combinations that are currently available in clinical practice. Future perspectives of BL/BLI armamentarium. Resistance developing for this class of antibiotics. Guests: Robert Bonomo. Professor, Department of Medicine, Pharmacology and Molecular Biology and Microbiology, Case Western Reserve University, Director of VA CARES Center, Cleveland, OH Patricia A. Bradford Antimicrobial Development Specialists LLC, Nyack, New York, USA This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at aac.asm.org. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership to sign up. Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript.

Meet Matt Ode, now 31 at the recording of this podcast, married, and a man who survived Stage 3C testicular cancer. Diagnosed at age 24, Matt was a personal trainer in excellent shape and enjoying life until he received his cancer diagnosis. His treatment began with chemotherapy, and then, surgery to remove an 11-centimeter tumor in his small intestine followed by multiple complications.  Faith played, and continues to  play, a vital and primary role in Matt's story, details he shared in this podcast. Matt's mom had people praying all over the world for his recovery. He endured two comas - one that happened on its own, and later, an induced coma after cardiac arrest. His girlfriend, now wife Lauren, traveled this journey with him, and listeners will learn more about her support. And now, after years of hard work and internal discovery, Matt gives back to those with cancer in many ways.His Facebook group - Cancer/ Patient Survivor Network: Take Back Your Life From Cancer- began in 2020 and has more than 6,000 followers. In 2023, he introduced a second Facebook group to help cancer survivors find the path they want to take using their own unique talents.This is Part 1 of Matt Ode's story. Learn more about this vibrant, enthusiastic, and energetic young man, helping people transform their minds, body and spirit as a testicular cancer survivor.VIsit the Max Mallory Foundation to listen to this and past episodes of Don't GIve Up on Testicular Cancer.Support the showFind us on Twitter, Instagram, Facebook & Linkedin. If you can please support our nonprofit through Patreon.

Dr Srdan Verstovsek from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses new data with myeloproliferative neoplasms presented at the 2022 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/MPN).

Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayDLBCL22).

joniradio.org

How best to support one's body when undergoing chemotherapy is a question discussed by culinary medicine expert Dr. Sabrina Falquier and naturopath and functional medicine doctor Easter Ho. They examine whether a plant-based diet is recommended during or after chemotherapy and look at issues around iron absorption from plant sources.As referenced in the episode:Subscribe for Four Sigmatic products and save 30% with discount code AFN.Subscribe to Doctors+ Premium Episodes on Apple Podcasts.

What are the Wings of Love? How can someone help a loved one when they're diagnosed with a potentially life-threatening condition? Can we still enjoy life after dealing with cancer?Tara Reynolds developed Wings of Love, a 48-card oracle deck featuring butterflies and moths, to help terminally ill patients and their families come to terms with an impending death. As a two-time cancer patient, she was struck by the lack of support materials available for end-stage patients. Before she leaves this earth, she'd like to change that.Tara and Wings of Love are available on:Etsy, Instagram & Facebook Earth Angels Oracles#wingsofloveLinks to “Bereaved But Still Me” Social Media and Podcast Pages:

Dr Richard Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses new data in acute myeloid leukemia and myelodysplastic syndromes presented at the 2022 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/AMLMDS).

In this episode of The Healers Café, Manon Bolliger (facilitator and retired naturopath with 30+ years of practice) with Sylvie Beljanski about nonprofit, whose working towards curing cancer the natural way For the transcript and full story go to: https://www.drmanonbolliger.com/sylvie-beljanski     Highlights from today's episode include: Sylvie Beljanski 14:49 I think we have to be relentless. We have to keep speaking. Keep publishing, keep being there for all the people who want to learn about their own health and take it as they want to learn about how to take care of themselves, what is available to them naturally. Sylvie Beljanski So here we have a natural product which is going to help preserve bone marrow to do its own work without toxicity and therefore it means all the families of white blood cells are going to be created without any imbalance without growth factor and so on. Sylvie Beljanski So, when you have something that really really works, it finds its way one way or another. It is at some point recognized and therefore, never give up because it will eventually be recognized by good people with an open mind that will recognize the value of the science and give it a chance.   ABOUT SYLVIE BELJANSKI: Sylvie Beljanski, a French lawyer by trade, is a health advocate for holistic medicine, public speaker, internationally known author and entrepreneur. She is the Founder and Executive Vice President of The Beljanski Foundation, whose mission is to research natural approaches to cancer. She is also the CEO of Maison Beljanski, an international dietary supplement company. Ms. Beljanski is the award winning author of "Winning The War On Cancer: The Epic Journey Towards a Natural Cure". This book has helped propel Ms. Beljanski to be a sought-after speaker at health and wellness conferences globally, where she has educated thousands of people about scientific breakthroughs in the field of integrative medicine. Core purpose/passion: The Beljanski Foundation's mission is to sponsor research programs with various natural extracts recognized by Dr. Mirko Beljanski for their anticancer properties. Research has entailed programs on prostate cancer at Columbia University, including advanced prostate cancer that no longer responds to chemotherapy, as well as ovarian and pancreatic cancers at Kansas University Medical Center. All of these studies were completed using the same botanical extracts. They have been reported to be effective on both males and females and have also exhibited great synergy with a variety of chemotherapies. Research studies have proven that these same extracts are also effective against cancer stem cells, those cells deemed to be responsible for cancer relapse and metastasis. Passionate does not do justice for how driven I am to share the message about the effects and possibility for the extracts to save people's lives. Cancer researchers are all pursuing different goals. Some want to have something approved by the FDA, some want to milk an old patent into a new one and provide a new life to an old, ineffective molecule, and some simply want to cure people. All of these goals are very different and it is difficult to imagine that they could work together. However, since a number of prestigious universities have published their results with several Beljanski extracts, I have seen increased interest from researchers at other institutions and I would love to see The Beljanski Foundation establish new partnerships across the board. There is still so much research to be done. Website | Facebook  |  Instagram | YouTube | LinkedIn | Twitter | WinningTheWarOnCancer.com   ABOUT MANON BOLLIGER As a recently De-Registered board-certified naturopathic physician & in practice since 1992, I've seen an average of 150 patients per week and have helped people ranging from rural farmers in Nova Scotia to stressed out CEOs in Toronto to tri-athletes here in Vancouver. My resolve to educate, empower and engage people to take charge of their own health is evident in my best-selling books:  'What Patients Don't Say if Doctors Don't Ask: The Mindful Patient-Doctor Relationship' and 'A Healer in Every Household: Simple Solutions for Stress'.  I also teach BowenFirst™ Therapy through Bowen College and hold transformational workshops to achieve these goals. So, when I share with you that LISTENING to Your body is a game changer in the healing process, I am speaking from expertise and direct experience". Mission: A Healer in Every Household! For more great information to go to her weekly blog:  http://bowencollege.com/blog.    For tips on health & healing go to: https://www.drmanonbolliger.com/tips   ABOUT THE HEALERS CAFÉ: Manon's show is the #1 show for medical practitioners and holistic healers to have heart to heart conversations about their day to day lives. Follow on Social – Facebook | Instagram | LinkedIn | YouTube | Twitter | Linktr.ee | Rumble   * De-Registered, revoked & retired naturopathic physician after 30 years of practice in healthcare. Now resourceful & resolved to share with you all the tools to take care of your health & vitality!   Remember to subscribe if you like our videos. Click the bell if you want to be one of the first people notified of a new release.  

When performing patient education with a patient who is receiving external radiation therapy, which of the following statements is MOST correct? Find it all out in this podcast!  Be prepared for the NPTE so that you can pass with flying colors! Check out www.ptfinalexam.com/podcast for more information and to stay up-to-date with our latest courses and projects.

Dr Erica Mayer from the Dana-Farber Cancer Institute in Boston, Massachusetts and Dr Ruth O'Regan from the University of Rochester in Rochester, New York discuss new developments in ER-positive breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayERPositiveBreastCancer23).

Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy discusses recent therapeutic advances in HER2-positive metastatic breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2PositivemBC22).

In 2022, Dr. Maura Abbott, Associate Professor of Nursing at the Columbia University School of Nursing, served as faculty for i3 Health's CME/NCPD approved activity, New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia. Now, in this follow-up interview with Oncology Data Advisor, Dr. Abbott reinforces the importance of educating patients who are at risk for chemotherapy-induced neutropenia and shares some of the therapeutic developments in both prevention and management that are coming down the pipeline in the near future. Click here to view and claim credit for New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/new-cme/44-policies/503-i3health-com-cin

Dr. Beverly Moy is back on the ASCO Guidelines Podcast to discuss the latest guideline rapid recommendation update regarding sacituzumab govitecan for patients with hormone receptor-positive HER2-negative metastatic breast cancer based on recent evidence published in TROPiCS-02. Dr. Moy reviews how this update intersects with the previous rapid recommendation update on trastuzumab deruxtecan and future areas of research that may impact further updates to this evidence-based guideline. Read the latest update, "Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update" at www.asco.org/breast-cancer-guidelines. TRANSCRIPT Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one at asco.org/podcasts.   My name is Brittany Harvey and today I'm interviewing Dr. Beverly Moy from Massachusetts General Hospital in Boston, Massachusetts, lead author on ‘Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update'. Thank you for being here, Dr. Moy. Dr. Beverly Moy: Thank you for having me, Brittany. I'm glad to be here. Brittany Harvey: Then first, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The full conflict of interest information for this guideline panel is available in line with the publication of the guideline in the Journal of Clinical Oncology. Dr. Moy, do you have any relevant disclosures that are directly related to this guideline topic? Dr. Beverly Moy: I do not have any relevant disclosures. Brittany Harvey: It's great to have you back on the podcast. Last we spoke, we were discussing the July 2022 rapid update of this guideline regarding the use of trastuzumab deruxtecan. What prompted the second rapid update to the guideline? Dr. Beverly Moy: Thank you very much for that question, Brittany. The guidelines committee decided to issue another rapid guideline update because of the second interim analysis results of the TROPiCS-02 trial. This trial showed that sacituzumab govitecan had a significant improvement of over three months in overall survival compared to chemotherapy of physician's choice in patients with pretreated metastatic hormone receptor positive and HER2/neu-negative breast cancer. So we felt that the strength of this data compelled the ASCO guideline ommittee to issue yet another update. Brittany Harvey: Understood. So then, based off this strong data that you just mentioned from TROPiCS-02, what is the updated recommendation from the guideline expert panel? Dr. Beverly Moy: So the guidelines expert panel really wanted to get this information out because we felt compelled that clinicians should be aware that sacituzumab govitecan is another treatment option for patients with endocrine-resistant metastatic hormone receptor- positive and HER2-negative breast cancer. So we felt that clinicians may use this drug in patients who have received at least two prior treatments in a metastatic setting. Brittany Harvey: Okay, you just mentioned this is one of several treatment options. So as this new recommendation is implemented, what should clinicians know? Dr. Beverly Moy: So, I think that clinicians really need to be aware that sacituzumab govitecan, which is a newer drug, as an antibody drug conjugate, it really does have a role in patients with metastatic hormone receptor positive, HER2/neu-negative endocrine-refractory breast cancer. I think clinicians have been used to this drug in the setting of metastatic triple-negative breast cancer, but the results of theTROPiCS-02 trial would show us that it actually has a lot of efficacy and even an overall survival benefit in patients with metastatic hormone receptor-positive breast cancer. So clinicians should be made aware that this is a treatment option that does give an overall survival benefit. Brittany Harvey: Great. It's great to hear that there's an overall survival benefit with this drug. So, in addition to that, how does this rapid update impact patients with hormone receptor-positive HER2-negative metastatic breast cancer? Dr. Beverly Moy: So I think that it's important for clinicians to remember that patients with metastatic hormone receptor-positive HER2/neu-negative breast cancer, the first-line therapies are endocrine therapy and targeted therapies. But when their disease becomes endocrine refractory, we have several treatment options, and usually the standard is sequential single-agent chemotherapy. What this guideline update is telling us is that sacituzumab govitecan, when compared to other treatments of physician's choice, really does improve overall survival and progression-free survival. So it really should be considered. Brittany Harvey:  Excellent. And then finally, are there ongoing research developments that the panel is keeping an eye on for any future updates to this guideline? I know this guideline was last published in 2021 and there's already been two rapid updates to it. Dr. Beverly Moy: Yes, that's a really great question, Brittany, because this is a very active field, and I think that it's important actually to take this guideline update with sacituzumab govitecan in the context of our last guideline update, which, as you said earlier, was with the other antibody drug conjugate trastuzumab deruxtecan. That was our last guideline update in patients who had what we call metastatic HER2 low disease, where trastuzumab deruxtecan had a significant overall survival advantage as well. So what these two guideline updates are really pointing out is that there's this new class of drugs, these antibody drug conjugates, that have so much promise and so much activity in metastatic breast cancer, whether it's hormone receptor-positive or hormone receptor-negative. So future research really has to help us clarify how do we sequence these drugs most appropriately now that we have these two very active treatment options that have a significant overall survival advantage. And then research also has to really guide us into the resistance mechanisms that may be in common or not in common with these two antibody drug conjugates. So I think that we're really looking at results of future trials to see how best to sequence them, if they should be used earlier in treatment in the metastatic setting, and we await the results of those trials. Brittany Harvey: Absolutely. We'll look forward to those future research developments and work with you and the panel to continuously update these guidelines. So I want to thank you so much for your work leading these guideline rapid recommendation updates, and thank you for your time today, Dr. Moy. Dr. Beverly Moy: Thank you, Brittany, for having me. Brittany Harvey: And thank you to all our listeners for tuning in to the ASCO Guidelines podcast series. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Dr. Skyler Hamilton is interviewed by Dr. Liz for an update about how she healed her Multiple Sclerosis (MS) as well as her work as a psychotherapist in Quantum biology and healing with hypnosis. She wows us with her explanation of quantum healing and how combined with hypnosis can change cellular pathways, people's health, and ultimately their lives. She gives an easy way to begin this process at home for yourself. Her original episode recorded in 2017, re-aired on 01/13/2023 (episode HM258 Best Of Decrease Symptoms of MS and Side-Effects of Chemotherapy with Dr. Skyler Hamilton). Please note that hypnosis is not a cure for medical conditions but is discussed in this episode as a way to reduce side-effects and reframe treatment as healing and strength-giving. About Dr. Skyler Hamilton Dr. Skyler Hamilton Ph.D., is a Mind Body Psychologist, specializing in brain-gut disorders and the somatization of stress, anxiety, and trauma. Dr. Hamilton's methods include cutting-edge, evidenced-based techniques including neurolinguistic re-programming, psychoneuroimmunology, hypnosis, meditation, family systems and attachment theories. Her approach is evidenced based but is built upon a genuine, empathic bond. Dr. Hamilton has developed a unique evidence based neuroscience approach for treating inflammatory diseases. Her approach incorporates the power of the mind and Hypnosis for successful management of these extraordinarily difficult cases.    See more about her at https://www.drsky.net   About Dr. Liz Winner of numerous awards including Top 100 Moms in Business, Dr. Liz provides psychotherapy, hypnotherapy, and hypnosis to people wanting a fast, easy way to transform all around the world. She has a PhD in Clinical Psychology, is a Licensed Mental Health Counselor (LMHC) and has special certification in Hypnosis and Hypnotherapy. Specialty areas include Anxiety, Insomnia, and Deeper Emotional Healing. See more about Dr. Liz and get Free hypnosis files at http://bit.ly/drlizhypnosis -------------- Do you have Chronic Insomnia? Find out more about Dr. Liz's Better Sleep Program at https://bit.ly/sleepbetterfeelbetter Search episodes at the Podcast Page http://bit.ly/HM-podcast Help yourself with Hypnosis Downloads by Dr. Liz! http://bit.ly/HypnosisMP3Downloads --------- A problem shared is a problem halved. In person and Online hypnosis and CBT for healing and transformation. Schedule your free consultation at https://www.drlizhypnosis.com. Listened to in over 140 countries, Hypnotize Me is the podcast about hypnosis, transformation, and healing. Certified hypnotherapist and Licensed Mental Health Counselor, Dr. Liz Bonet, discusses hypnosis and interviews professionals doing transformational work Thank you for tuning in! Please subscribe to auto-download new episodes to your listening device.

Chris and Carrie are joined by Mr. Kevin Crowe, Founder of Give A Mile. Imagine your loved one is nearing the end of life and you cannot afford a flight to see them for one last visit. Listen to hear how Kevin's organization can help! Have airline miles you aren't going to use? Donate them! Visit www.giveamile.org for more information.

Today, I am blessed to have here with me Damon Sununtnasuk. He is the founder and CEO of the Sunt Group and Palmara Health which is previously named Nature Cure Labs. He has received numerous awards and recognitions in 2020. These awards include but are not limited to Company of the Year - Health Products & Services, Health & Wellness Nutrition Manufacturer of the Year, 10 Most Influential CEOs in 2022, and many more. Damon is also part of the board of directors of the University of Florida Alumni Association. Damon was born and raised in Florida where he graduated Magna Cum Laude from the University of Florida with the degree of Bachelor of Science in Business Administration. He had an opportunity to live overseas which is why he was able to take his Master of Business Administration at the University of Cambridge.  After living overseas, Damon came back to the United States in the year 2015. During this time, he experienced various serendipity. One of them is not having a way of looking after his health. At the time, he was also surrounded by the technological industry, entrepreneurial spirit, and startups. Aside from that, his group of friends was also into MCTs for health purposes which triggered his curiosity. There was even a time when he discovered "oil pulling" which is the process of putting coconut oil in the mouth for 10 minutes before spitting it out to help remove dirt and help maintain the health of your teeth and gums. After these events, he began to research MCTs where he was able to discover the different therapeutic benefits of Medium-Chain Triglycerides. Together with his desire to improve his health and the will to help others, he was able to establish his company in 2015. Currently, they have 3 manufacturing facilities and 35 warehouses in the United States. In this episode, Damon discusses Medium-Chain Triglycerides, specifically Monolaurin, and their role and benefits to the body. He talks about different studies about it and briefly discusses how these supplements are collected and made. He also mentions the Monolaurin product that his company offers. Get your monolaurin supplements with a discount here: Visit https://www.naturalcurelabs.com/products/?ref=KetoKamp Use the coupon code ketokamp for 10% off Take my FREE toxicity quiz to determine your level of toxicity. Visit www.toxicmiami.com for the free quiz. / / E P I S O D E   S P ON S O R S  Paleo Valley beef sticks, apple cider vinegar complex, organ meat complex & more. Use the coupon code KETOKAMP15 over at https://paleovalley.com/ to receive 15% off your entire order. Upgraded Formulas Upgraded Magnesium & Charge Electrolyte Supplements: http://www.upgradedformulas.com Use KK15 at checkout for 15% off your order.  Text me the words "Podcast" +1 (786) 364-5002 to be added to my contacts list.  [03:36] Medium Chain Triglycerides and its Benefits in the Body Plant fats contain medium chain triglycerides, coconut oil is a common example. 90% of the fats in coconut oil are saturated fats in which 50% of these saturated fats are MCTs. The health benefits of MCTs have been studied over the years. Some people put it on their coffee, protein shakes, food and etc. When MCTs have been converted in the body, it becomes monolaurin. The three main types of MCTs are Capric, Caprylic, and Lauric Acid. They bring benefits to the body by giving immune support and regulation as well as an aid in ketosis. Damon is focusing on Lauric Acid as based on their research, it helps in immune, digestive, and inflammatory support. [11:33] Everything About Monolaurin: Role and Benefits in the Body Damon read a study about the use of Monolaurin to fight off Giardia Lamblia, one of the most common causes of malnutrition. One of the studies Damon has read used Monolaurin to try cure Giardia Lamblia on animal subjects in which the cure rates reached over 90%.  On the other hand, Damon has also read another study wherein Monolaurin was used on the animal subjects first before giving Giardia Lamblia. 60% of the test subjects didn't get sick. Research shows that Monolaurin helps in breaking down the protective envelope of the DNA and RNA viruses. Breast milk contains 6.5% of Monolaurin. Monolaurin can be found on coconut oil and palm oil. However, palm oil can only be harvested on sensitive environments which can affect natural habitats which is why coconut oil is more preferred. [20:21] The Different Ways You Can Take Monolaurin Before taking any supplements, you must contact a health professional in order to determine the right dosage for you to take. Introductory dose - Taking Monolaurin once a day, once every other day, and slowly increasing that up into the therapeutic dosage you're looking to get as an individual. Maintenance - In this way, monolaurin is taken daily to help maintain and regulate the healthy immune response.  Some people also take Monolaurin when they feel sick or immunocompromised.  [25:30] How Safe is Monolaurin for the Body? Monolaurin, under its chemical name 'Glycerol Monolaurin', is included on the 'Generally Recognized as Safe' list of the FDA. Different studies have not indicated a limit on the use of Monolaurin. Monolaurin impacts gut health. Research suggests that the continuous use of Monolaurin does not creates resistance in the body. [27:38] What Should You Do Before Buying a Product? Check out product testimonials posted on the website or marketplaces. Some product reviews are incentivized and not true so you should try and search about it first. Research through trusted websites like PubMed, familiarized yourself on different products, the science, the background, then the mechanics of it all and sort of trust the science and not necessarily someone's opinion. AND MUCH MORE! Resources from this episode:  Website Get your monolaurin supplements with a discount here: Visit https://www.naturalcurelabs.com/products/?ref=KetoKamp Use the coupon code ketokamp for 10% off Check out Nature Cure Labs on social meida Facebook: https://www.facebook.com/NaturalCureLabs Instagram: https://www.instagram.com/naturalcurelabs/ Check out Damon Sununtnasuk LinkedIn: https://www.linkedin.com/in/damonsun/ Academic Resources: PubMed: https://pubmed.ncbi.nlm.nih.gov/ Monolaurin and More: https://www.monolaurinandmore.com/articles/monolaurin-keto-diet Studies referenced: Using monolaurin pre- and post- infection: Fahmy ZH, Aly E, Shalsh I, Mohamed AH. The effect of medium chain saturated fatty acid (monolaurin) on levels of the cytokines on experimental animal in Entamoeba histolytica and Giardia lamblia infection. African Journal of Pharmacy and Pharmacology. January 2014. https://academicjournals.org/journal/AJPP/article-abstract/0C0410F43049 Monolaurin and Ketosis: Avgerinos, Konstantinos I, et al. “Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies.” Ageing Research Reviews, 2020.  https://pubmed.ncbi.nlm.nih.gov/31870908/ Customer Reviews: (you can choose to read a couple testimonials in the intro / outro) 600mg Premium Monolaurin: https://www.amazon.com/Natural-Cure-Labs-Premium-Monolaurin/dp/B017RHHEVG?ref_=ast_sto_dp&th=1#customerReviews 800mg Extra Strength: https://www.amazon.com/Natural-Cure-Labs-Strength-Monolaurin/dp/B07GQ1RQHW?ref_=ast_sto_dp&th=1#customerReviews 1:1 L-Lysine + Monolaurin: https://www.amazon.com/Natural-Cure-Labs-L-Lysine-Monolaurin/dp/B07VNV2ZKP?ref_=ast_sto_dp#customerReviews  Monolaurin mechanisms in the body: Research on monolaurin's impact on cell mechanisms or organs (ie: liver) is limited, but here is some research. Please don't attribute this to me, as it could be seen as a disease claim. “When monolaurin is consumed, it circulates in the bloodstream & is metabolized in a delayed fashion over 8-12 hours. Monolaurin is not excreted or detoxified out of the body. Instead, it is turned into energy in the form of ketones, [which in turn can] support ketone levels in the body.” -          https://dralexrinehart.com/articles/monolaurin-a-secret-coconut-oil-compound-with-powerful-immune-benefits/ “When coconut oil is consumed, the medium-chain triglycerides (MCTs) are broken down into individual medium chain fatty acids and monoglycerides, which can kill or inactivate pathogenic microorganisms inside the body. The antiviral action, attributed to monolaurin (the monoglyceride of lauric acid), is that of solubilizing the lipids and phospholipids in the envelope of the pathogenic organisms causing the disintegration of their outer membrane. There is also evidence that MCFA interfere with the organism's signal transduction and the antimicrobial effect in viruses is due to interference with virus assembly and viral maturation.” -          Arora, Rajesh, et al. “Potential of Complementary and Alternative Medicine in Preventive Management of Novel H1N1 Flu (Swine Flu) Pandemic: Thwarting Potential Disasters in the Bud.” Evidence-Based Complementary and Alternative Medicine, 13 Oct. 2010. “[Monolaurin] removes the M protein from the virus envelope resulted in loss of envelope integrity, which is essential for virus infectivity… the loss of envelope integrity results in loss of infectious virus titer” -          Hierholzer, John C, and Jon J Kabara. “In Vitro Effects of Monolaurin Compounds on Enveloped DNA and RNA Viruses.” Journal of Food Safety, vol. 4, no. 1, Mar. 1982, pp. 1–12. “Medium-chain saturated and long-chain unsaturated fatty acids, on the other hand, were all highly active against the enveloped viruses... Antiviral fatty acids were found to affect the viral envelope, causing leakage and at higher concentrations, a complete disintegration of the envelope and the viral particles. They also caused disintegration of the plasma membranes of tissue culture cells resulting in cell lysis and death.” -          Thormar, H, and et al. “Inactivation of Enveloped Viruses and Killing of Cells by Fatty Acids and Monoglycerides.” Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.31.1.27. Watch Keto Kamp on YouTube: https://www.youtube.com/channel/UCUh_MOM621MvpW_HLtfkLyQ Take my FREE toxicity quiz to determine your level of toxicity. Visit www.toxicmiami.com for the free quiz. / / E P I S O D E   S P ON S O R S  Paleo Valley beef sticks, apple cider vinegar complex, organ meat complex & more. Use the coupon code KETOKAMP15 over at https://paleovalley.com/ to receive 15% off your entire order. Upgraded Formulas Upgraded Magnesium & Charge Electrolyte Supplements: http://www.upgradedformulas.com Use KK15 at checkout for 15% off your order.  Text me the words "Podcast" +1 (786) 364-5002 to be added to my contacts list.  *Some Links Are Affiliates* // F O L L O W ▸ instagram | @thebenazadi | http://bit.ly/2B1NXKW ▸ facebook | /thebenazadi | http://bit.ly/2BVvvW6 ▸ twitter | @thebenazadi http://bit.ly/2USE0so ▸ tiktok | @thebenazadi https://www.tiktok.com/@thebenazadi Disclaimer: This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast including Ben Azadi disclaim responsibility from any possible adverse effects from the use of information contained herein. Opinions of guests are their own, and this podcast does not accept responsibility of statements made by guests. This podcast does not make any representations or warranties about guests qualifications or credibility. Individuals on this podcast may have a direct or non-direct interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.

Please note that this interview was done before Dr. Hamilton had completed her PhD. Her update about her MS and the work she is doing now airs 01/20/2023 in episode HM259 “Quantum Biology and Healing with Dr. Skyler Hamilton.” Dr. Skyler Hamilton is interviewed by Dr. Liz about how she healed her Multiple Sclerosis (MS) and how her husband used hypnosis to reduce side-effects of chemotherapy to the point where he was able to run 3 miles a day during his treatments and not miss a day of work. Please note that hypnosis is not a cure for medical conditions but is discussed in this episode as a way to reduce side-effects and reframe treatment as healing and strength-giving. We'll Learn: Skyler's first experiences with hypnosis through free diving and a 46 minute birth of her second child. How Skyler used hypnosis to go from being in a wheelchair with home health aides to heal her own MS. How her husband used hypnosis to reduce side-effects of chemotherapy treatment and live years past his original estimate of 18 months. How her husband uses hypnosis to maintain his progress. How hypnosis works on a cellular level. Skyler's work with Opioid addiction and Opioid recovery and the transformation she begin to see with hypnosis. Skyler's research on hypnosis for healing on the cellular level. **Correction: Skyler mentions Hep B when discussing addiction when she meant to say Hep C. About Dr. Skyler Hamilton Dr. Skyler Hamilton Ph.D., is a Mind Body Psychologist, specializing in brain-gut disorders and the somatization of stress, anxiety, and trauma. Dr. Hamilton's methods include cutting-edge, evidenced-based techniques including neurolinguistic re-programming, psychoneuroimmunology, hypnosis, meditation, family systems and attachment theories. Her approach is evidenced based but is built upon a genuine, empathic bond. Dr. Hamilton has developed a unique evidence based neuroscience approach for treating inflammatory diseases. Her approach incorporates the power of the mind and Hypnosis for successful management of these extraordinarily difficult cases.  See more about her at https://www.drsky.net About Dr. Liz Winner of numerous awards including Top 100 Moms in Business, Dr. Liz provides psychotherapy, hypnotherapy, and hypnosis to people wanting a fast, easy way to transform all around the world. She has a PhD in Clinical Psychology, is a Licensed Mental Health Counselor (LMHC) and has special certification in Hypnosis and Hypnotherapy. Specialty areas include Anxiety, Insomnia, and Deeper Emotional Healing. See more about Dr. Liz and get Free hypnosis files at http://bit.ly/drlizhypnosis -------------- Do you have Chronic Insomnia? Find out more about Dr. Liz's Better Sleep Program at https://bit.ly/sleepbetterfeelbetter Search episodes at the Podcast Page http://bit.ly/HM-podcast Help yourself with Hypnosis Downloads by Dr. Liz! http://bit.ly/HypnosisMP3Downloads --------- A problem shared is a problem halved. In person and Online hypnosis and CBT for healing and transformation. Schedule your free consultation at https://www.drlizhypnosis.com. Listened to in over 140 countries, Hypnotize Me is the podcast about hypnosis, transformation, and healing. Certified hypnotherapist and Licensed Mental Health Counselor, Dr. Liz Bonet, discusses hypnosis and interviews professionals doing transformational work Thank you for tuning in! Please subscribe to auto-download new episodes to your listening device.

Dr Manish Shah from Weill Cornell Medicine in New York City discusses current approaches to the management of upper GI malignancies and the potential future role of novel therapies for patients with these cancers.  CME information and select publications here (http://www.researchtopractice.com/OncologyTodayGastroesophageal22).

Dr Trevor Bachmeyer MD (IG: @Smashwerx ) is the creator of  @SmashweRx  and the Spartan Company. He is a survivor of non-Hodgkin's lymphoma and had a lung removed due to a tumor yet still creates fitness content for Youtube on a daily basis. ——————————————————— Michael's Men of Action program is a Master's course dedicated to helping people elevate their social lives by building elite social circles and becoming higher status. Click the link below to learn more: https://m.moamentoring.com/podcast ———————————————————— Become an affiliate for MOA Mentoring: https://www.moamentoring.com/earn Subscribe on Youtube: https://www.youtube.com/user/MichaelSartain Listen on Apple Podcast: https://podcasts.apple.com/us/podcast/the-michael-sartain-podcast/id1579791157 Listen on Spotify: https://open.spotify.com/show/2faAYwvDD9Bvkpwv6umlPO?si=8Q3ak9HnSlKjuChsTXr6YQ&dl_branch=1 Filmed at Sticky Paws Studios: https://m.youtube.com/channel/UComrBVcqGLDs3Ue-yWAft8w 0:00 Intro 1:04 *Smashwerx 2:57 **52 muscles control the hip 3:47 ***Competency 4:26 ****Non-Hoskins lymphoma 6:40 ***Self deletion 7:56 ***I've got a why 8:58 ***It's got to get done 9:31 ****Would you do this to your boy? 11:11 Remission 12:32 ***I'm still here 13:15 ****You're not welcome here 15:01 *Chemotherapy 18:32 **Virus to attack cancer 21:02 Overweight trainer 22:27 *Rule #5 23:04 ***HGH on tumors 24:55 ***Durable babies, natural selection 27:02 ****Weakest mammals 31:42 Spartan Program 32:12 ***Thoracic surgery 36:12 ***Medical treatment 41:40 Tumor 45:46 ***I refused to quit 46:28 Slept in my car 47:02 Medical degree 48:52 ****You can't buy another day 50:09 ***Treating depressed 53:07 ***You can't catch depression 58:24 Learning these hacks 1:01:02 Body Hacks 1:02:09 Lower back pain 1:04:49 Sciatic pain 1:09:08 Natural Selection 1:11:05 Deadlifts 1:13:53 Pull-ups 1:16:14 Shoulder pain 1:17:44 Knee pain 1:22:16 Injuries 1:23:26 Audiobooks 1:28:00 **Speed it up 1:30:35 Read at that speed 1:32:58 **If you slow me down I do worse 1:34:29 Time compression 1:38:17 Multitasking 1:40:37 ***Dealing with haters 1:43:57 ****David Goggins 1:46:39 ***Reverse engineer mentors 1:49:18 The Spartan company, Smashwerx 1:55:50 Outro

Dr. Venable is Board Certified as a medical oncologist from the American College of Veterinary Internal Medicine. Dr. Venable has always been surrounded by animals growing up on a farm in the Midwest. She obtained her veterinary degree from the University of Missouri and graduated cum laude. After veterinary school, Dr. Venable pursued further training as a small animal intern at the University of Georgia. She then completed her 3-year medical oncology residency at the world-renowned Colorado State Flint Animal Cancer Center. During her residency, she achieved a master's degree and studied new cancer therapies and clinical trials. She continues to seek out clinical trials and cutting-edge therapies for her patients. Dr. Venable has authored numerous publications and has been a speaker on local and national levels. She is the founder of Pet Cancer Care Consulting an innovative teleconsulting service which consults with the family vet and pet owner together to give personalized responses and needed information to make an informed decision on treatments. She is also a VIN consultant and was an adjunct professor of veterinary oncology at Midwestern University. She is a member of many organizations and currently a director to the board of the Arizona Veterinary Medical Association. Her oncology philosophy is one of a team-based approach with the family and referring veterinarians for compassionate, individualized care, and optimal quality of life for cancer patients and their families. Dr. Venable enjoys the outdoors and being on the trail with her wonderful husband and their young daughters. Service opportunities are important to them as they volunteer at church and abroad as her husband works for a non-profit building schools in the developing world. Together they go on projects all over the globe with Be The Change Volunteers. 

"The “X” Suture: A Versatile Technique for Nail Apparatus Surgery." Caycedo, Isabela Dorado, Florence Dehavay, and Bertrand Richert. Dermatologic Surgery 48.12 (2022): 1362-1364."Chemotherapy-associated paronychia: Do not forget the children." Borgia, Paola, et al. Journal of the American Academy of Dermatology 88.1 (2023): e59.

On Today's Show: I didn't go to my office Christmas party.

Christina Myers and Kevin Reardon's daughter Olivia has been through a myriad of serious health issues in her still very young life. Born 10 1/2 weeks prematurely, she had heart surgery when she was a month old, and then after a healthy period that lasted 3 years, she was diagnosed with Stage 4 Aveolar Rhabdomayosarcoma.  Olivia just completed her 51st out of 66 Chemotherapy treatments, has returned to school as a 5th grader, and as 2023 goes on, the hope is that she will return to full health and a peaceful life as soon as possible. Christina and Kevin will also talk about their Olivia Strong Foundation, which they started in March of 2022 with the hope that it will become an important Regional non-profit to help as many kids and families as possible in the pediatric cancer fight. This non- profit is based in Charlotte, North Carolina. 

While he was still in Chemotherapy, Brian convinced his parents to hit the Nordic jumps at his home in Steamboat Springs, Colorado. With each bigger jump he was more and more hooked. Then he convinced them to let him join the program. Nordic Combined became his sport when he followed his friends not realizing that it meant the pain of Cross-Country skiing, but he soon realized that he had a talent for that pain and was rewarded for being tough the way that he had been as a little kid having to get his blood drawn. That joy and toughness led to two Olympic and five World Championship Teams. Now, he works with one of the preeminent knee clinics in the world, giving so many others an opportunity to live fully. 

Dr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMetastaticBladderCancer22).

Carrie is joined by Vernen Todd, her good friend and caregiver during her 2013 sepsis crisis following reconstruction surgery. The two discuss the trauma Vern experienced as a caregiver and he weighs in on a recent episode of dating after breast cancer. #hwcarepodcast #trauma #caregiversupport #thecareprojectinc #breastcancer